Cancer BiologybioRxiv
The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer
M. Vigolo, C. Urech, S. Lamy…·S. Majumder
This paper evaluates the efficacy and safety of CB-103, a Notch inhibitor, in preclinical breast cancer models, showing synergistic effects with existing therapies.
DOI 10.3390/cancers15153957